Using topotecan and melphalan to treat retinoblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness and potential complications of administering topotecan and melphalan through intraocular injection in patients diagnosed with retinoblastoma. It aims to provide a treatment option that spares the eyeball while addressing the cancer. The study is designed as a Phase 3 interventional trial, focusing on the outcomes of these chemotherapy agents in a specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* diagnosed as retinoblastoma
* receiving eyeball-sparing treatment

Exclusion Criteria:

* disease progression during follow-up

Where it's running

• Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Huashen Yang — Sun Yat-sen University
• Study coordinator: Huasheng Yang
• Email: yanghs64@126.com
• Phone: +00862087331539

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding silibinin to standard daunorubicin or idarubicin therapy for newly diagnosed non‑M3 acute myeloid leukemia

  This trial will test whether adding silibinin (a liver‑protecting compound) to standard daunorubicin or idarubicin chemotherapy helps people with newly diagnosed non‑M3 acute myeloid leukemia.

  Recruiting Phase 4 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07561892

• Camrelizumab plus apatinib with or without FOLFOX chemotherapy for advanced liver cancer

  This research will test whether adding FOLFOX chemotherapy to camrelizumab plus apatinib helps adults with advanced hepatocellular carcinoma who have not received prior systemic treatment.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07267806

• High-dose Topotecan treatment for recurrent retinoblastoma with vitreous seeds

  This study is testing whether high-dose Topotecan can help patients with recurrent retinoblastoma and vitreous seeds keep their eye while fighting the tumor.

  Recruiting Early Phase 1 Eye & ENT Hospital of Fudan University · Shanghai, China · NCT06972602

• Personalized management for borderline resectable and locally advanced pancreatic cancer

  This study is testing if giving chemotherapy first can help people with borderline resectable and locally advanced pancreatic cancer have surgery and improve their chances of survival.

  Recruiting Oslo University Hospital · Bergen, Norway and 4 other locations · NCT06944587

• Impact of massage therapy on sleep in young cancer patients

  This study is testing whether personalized massage therapy can help young cancer patients in the hospital sleep better and feel less tired, anxious, and in pain during their treatment.

  Recruiting Children's Hospital of Philadelphia · Washington D.C., District of Columbia and 1 other locations · NCT06892158

• Linking RB1 genetic changes to eye tumors and metastasis

  We will use targeted long-read genetic sequencing on people with retinoblastoma to see if specific RB1 mutations match tumor features and the risk of spread.

  Recruiting University of Washington · Seattle, Washington · NCT06725173

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.